| 0.1338 -0.004 (-3.04%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.18 | 1-year : | 0.21 |
| Resists | First : | 0.15 | Second : | 0.18 |
| Pivot price | 0.13 |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.13 |
| MA(100) : | 0.29 |
MA(250) : | 1.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 31.1 |
D(3) : | 33.2 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 2.46 | Low : | 0.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARAV ] has closed above bottom band by 29.9%. Bollinger Bands are 93.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 74 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.15 - 0.15 | 0.15 - 0.15 |
| Low: | 0.13 - 0.13 | 0.13 - 0.13 |
| Close: | 0.14 - 0.14 | 0.14 - 0.14 |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Tue, 14 Nov 2023
Aravive Third Quarter 2023 Earnings: Beats Expectations - Simply Wall St
Wed, 18 Oct 2023
Aravive (NASDAQ: ARAV) stock up 62% - a truly weird analysis from Zacks - Dhaka Tribune
Fri, 13 Oct 2023
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tue, 05 Sep 2023
Aravive (NASDAQ: ARAV) stock up 27% - we think this is unlikely to persist - Dhaka Tribune
Thu, 03 Aug 2023
Aravive (NASDAQ: ARAV) down 50% - well, that drug doesn’t work then - Dhaka Tribune
Thu, 03 Aug 2023
Why Is Aravive (ARAV) Stock Down 58% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 47.5 (%) |
| Held by Institutions | 30.5 (%) |
| Shares Short | 3,580 (K) |
| Shares Short P.Month | 6,960 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.01 |
| Profit Margin | 0 % |
| Operating Margin | -323.5 % |
| Return on Assets (ttm) | -134.1 % |
| Return on Equity (ttm) | -476 % |
| Qtrly Rev. Growth | -44.5 % |
| Gross Profit (p.s.) | -0.79 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 6.69 |
| Price to Sales | 1.4 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|